Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-06-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding the appointment and remuneration of senior management at Shenzhen BGI Genomics Co., Ltd. It references compliance with company laws, stock exchange listing rules, and company articles of association. The content focuses on board and management personnel matters, specifically the nomination, appointment, and salary scheme of senior executives. There is no financial data, earnings information, or report publication mentioned. The document is not a full annual or interim report, nor is it a regulatory filing or announcement of voting results. It clearly fits the category of Board/Management Information (MANG) as it announces changes and opinions related to senior management appointments and compensation.
2021-06-16 Chinese
第三届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of the chairman of the third supervisory board of Shenzhen BGI Genomics Co., Ltd. It details the meeting procedures, voting results, and includes a resume of the elected chairman. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. The content focuses on board/management changes, specifically the election of a supervisory board chairman, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2021-06-16 Chinese
2021年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2021 second extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting methods, attendance, and detailed voting results for the election of board members and supervisors. It also includes legal opinions on the meeting's legality. The document is not a full annual or interim report, nor is it a transcript or presentation. It is a formal announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief announcement or a report publication notice.
2021-06-16 Chinese
关于受让控股子公司少数股东股权进展暨深圳医检完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a transaction where the company Shenzhen Huada Gene Co., Ltd. acquired minority equity interests in its subsidiaries, Shenzhen Medical Testing Laboratory and Beijing Medical Testing Co., Ltd., making them wholly owned subsidiaries. It details the transaction overview, signing of equity transfer agreements, payment completion, and completion of business registration changes. The document includes no financial statements or detailed financial performance data, but rather reports on corporate actions related to shareholding and equity structure changes. This fits the definition of a Capital/Financing Update (CAP) as it concerns changes in the company's capital structure through acquisition of minority interests in subsidiaries. The document length is under 5,000 characters and contains substantive information about the transaction, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is CAP with high confidence.
2021-06-15 Chinese
关于召开2021年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2021 second extraordinary general meeting of shareholders for Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (including cumulative voting for board and supervisory committee elections), registration details, and attachments such as proxy forms and voting instructions. The content focuses on the organization and procedural details of the shareholders' meeting, including election of board members and supervisors, but does not contain actual voting results or financial data. This type of document is a notice or announcement related to a shareholders meeting, specifically about the meeting itself and voting instructions, not the results or minutes. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA) if it contained results, but since it is a notice before the meeting, it is more aligned with Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. The document is over 7,000 characters and contains detailed voting instructions and proxy forms, consistent with PSI filings. Hence, the correct classification is PSI with high confidence.
2021-06-10 Chinese
关于股东减持计划期限届满暨实施情况的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a shareholder share reduction plan by specific shareholders. It details the number of shares reduced, the time period, and compliance with relevant securities laws and regulations. It does not contain financial statements or detailed financial performance data. It is a regulatory announcement about shareholding changes and compliance disclosures related to share reduction plans. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2021-06-10 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.